Table 3.
Comparison of predicted (red) and observed (black) vaccine efficacy against infection at first challenge for the sporozoite infection model. Number in brackets represent the number of individuals infected in each tercile/total number in each tercile.
|
Anti-NANP Antibody Titres |
||||
|---|---|---|---|---|
|
Low 3399–18,512 |
Med 18513–34,139 |
High 34,140–74,710 |
All 3399–74,710 |
|
| Antibody Avidity Index | ||||
|
Low 28–44 |
41.0% | 61.3% | 76.6% | 62.4% |
| 66.7% (1/3) | 57.1% (3/7) | 80.0% (1/5) | 66.7% (5/15) | |
|
Med 45–59 |
64.9% | 85.2% | 92.9% | 76.8% |
| 62.5% (3/8) | 100% (0/3) | 80% (1/5) | 75% (4/16) | |
|
High 60–94 |
86.4% | 96.0% | 98.2% | 94.1% |
| 75.0% (1/4) | 100% (0/6) | 100% (0/5) | 93.3% (1/15) | |
|
All 28–94 |
65.5% | 77.9% | 89.8% |
77.7% (95% CI 64.2–87.2%) |
| 66.7% (5/15) | 81.3% (3/16) | 86.7% (2/15) | 78.2% (10/46) | |